Related Experiment Videos
Chronic pentamidine aerosol prophylaxis does not induce QT prolongation
C Thalhammer1, J R Bogner, G Lohmöller
1Medizinische Poliklinik, Universität München.
The Clinical Investigator
|April 1, 1993
Summary
Pentamidine aerosol prophylaxis, used for Pneumocystis pneumonia prevention in HIV patients, does not cause QT prolongation or long-QT syndrome, unlike intravenous pentamidine. This study found no cardiac risks associated with inhaled pentamidine use.
Area of Science:
- Pharmacology
- Cardiology
- Infectious Disease
Background:
- Intravenous pentamidine is associated with QT prolongation and Torsade de pointes tachycardias.
- Pentamidine aerosol prophylaxis is a common preventative treatment for Pneumocystis pneumonia in HIV-infected individuals.
Purpose of the Study:
- To investigate whether pentamidine aerosol prophylaxis induces QT prolongation.
- To assess the risk of long-QT syndrome associated with inhaled pentamidine.
Main Methods:
- A cross-sectional study compared QT intervals corrected for heart rate (QTc) in HIV patients on pentamidine aerosol prophylaxis, HIV patients without pentamidine, and non-HIV controls.
- A longitudinal study assessed QTc in HIV patients before and during long-term pentamidine aerosol prophylaxis.
- QTc measurements were performed blindly for treatment status.
Main Results:
- No significant difference in QTc was observed between patients receiving pentamidine aerosol prophylaxis, HIV-negative controls, and HIV-positive controls not on pentamidine.
- Long-term pentamidine aerosol prophylaxis did not alter QTc intervals in HIV-infected patients.
- The study found no evidence of QT prolongation or increased risk of long-QT syndrome with inhaled pentamidine.
Conclusions:
- Pentamidine aerosol prophylaxis does not induce QT prolongation.
- Unlike intravenous administration, inhaled pentamidine is not associated with an increased risk of long-QT syndrome.
- This finding supports the cardiac safety of pentamidine aerosol prophylaxis in HIV management.